Literature DB >> 24320749

Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling.

Jessica Ward1, Samantha N Spath, Brandon Pabst, Philip A Carpino, Roger B Ruggeri, Gang Xing, Anna E Speers, Benjamin F Cravatt, Kay Ahn.   

Abstract

Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Despite a high level of interest in MPO as a therapeutic target, there have been limited reports about MPO inhibitors that are suitable for evaluating MPO in pharmacological studies. 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A), has recently been reported to inhibit MPO by covalently modifying the heme prosthetic group. Here we report a detailed mechanistic characterization demonstrating that A possesses all the distinguishing features of a mechanism-based inactivator. A is a time-dependent MPO inhibitor and displays saturable inactivation kinetics consistent with a two-step mechanism of inactivation and a potency (k(inact)/K(I) ratio) of 8450 ± 780 M⁻¹ s⁻¹. MPO inactivation by A is dependent on MPO catalysis and is protected by substrate. A reduces MPO compound I to compound II with a second-order rate constant of (0.801 ± 0.056) × 10⁶ M⁻¹ s⁻¹, and its irreversible inactivation of MPO occurs prior to release of the activated inhibitory species. Despite its relatively high selectivity against a broad panel of more than 100 individual targets, including enzymes, receptors, transporters, and ion channels, we demonstrate that A labels multiple other protein targets in the presence of MPO. By synthesizing an alkyne analogue of A and utilizing click chemistry-activity-based protein profiling, we present that the MPO-activated inhibitory species can diffuse away to covalently modify other proteins, as reflected by the relatively high partition ratio of A, which we determined to be 15.6. This study highlights critical methods that can guide the discovery and development of next-generation MPO inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24320749     DOI: 10.1021/bi401354d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.

Authors:  Yang Li; Thota Ganesh; Becky A Diebold; Yerun Zhu; James W McCoy; Susan M E Smith; Aiming Sun; J David Lambeth
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

2.  Myeloperoxidase Inhibition Increases Neurogenesis after Ischemic Stroke.

Authors:  HyeonJu Kim; Ying Wei; Ji Yong Lee; Yue Wu; Yi Zheng; Michael A Moskowitz; John W Chen
Journal:  J Pharmacol Exp Ther       Date:  2016-08-22       Impact factor: 4.030

3.  Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.

Authors:  Benjamin Pulli; Muhammad Ali; Yoshiko Iwamoto; Matthias W G Zeller; Stefan Schob; Jenny J Linnoila; John W Chen
Journal:  Antioxid Redox Signal       Date:  2015-06-24       Impact factor: 8.401

4.  Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

Authors:  Franck Duclos; Lynn M Abell; David G Harden; Kristen Pike; Kimberly Nowak; Gregory A Locke; Gerald J Duke; Xiaoqin Liu; Gayani Fernando; Scott A Shaw; Benjamin P Vokits; Nicholas R Wurtz; Andrew Viet; Meriah N Valente; Sylwia Stachura; Paul Sleph; Javed A Khan; Ji Gao; Ashok R Dongre; Lei Zhao; Ruth R Wexler; David A Gordon; Ellen K Kick
Journal:  Medchemcomm       Date:  2017-10-26       Impact factor: 3.597

5.  29th Annual GP2A Medicinal Chemistry Conference.

Authors:  Jean-Jacques Helesbeux; Laura Carro; Florence O McCarthy; Vânia M Moreira; Francesca Giuntini; Niamh O'Boyle; Susan E Matthews; Gülşah Bayraktar; Samuel Bertrand; Christophe Rochais; Pascal Marchand
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-07

6.  Mechanism of reaction of chlorite with mammalian heme peroxidases.

Authors:  Christa Jakopitsch; Katharina F Pirker; Jörg Flemmig; Stefan Hofbauer; Denise Schlorke; Paul G Furtmüller; Jürgen Arnhold; Christian Obinger
Journal:  J Inorg Biochem       Date:  2014-02-28       Impact factor: 4.155

Review 7.  Activity-Based Protein Profiling (ABPP) of Oxidoreductases.

Authors:  Rita Fuerst; Rolf Breinbauer
Journal:  Chembiochem       Date:  2020-10-20       Impact factor: 3.164

Review 8.  Myeloperoxidase: a new target for the treatment of stroke?

Authors:  Yun-Chang Wang; Yu-Bao Lu; Xiao-Lan Huang; Yong-Feng Lao; Lu Zhang; Jun Yang; Mei Shi; Hai-Long Ma; Ya-Wen Pan; Yi-Nian Zhang
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.